DRUG
Terlipressin
The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
Status
Unknown
Phase
Phase 4
Enrollment
104
Locations
1
Results
Not posted
Publications
0
Study summary
The goal of this clinical trial is to evaluate the effect of intraoperative terlipressin on the incidence of early postoperative acute kidney injury in deceased doner liver transplantation. Patients were randomly divided into experimental group and control group by numerical randomization table. The experimental group was injected with terlipressin perioperative and the control group was injected with placebo
acute kidney injury is a relatively common complication in patients with liver transplantation. Most centers have established prediction models for acute kidney injury after liver transplantation, but the incidence cannot be reduced through perioperative anesthesia management. As an vasopressin receptor agonist, terlipressin can increase blood pressure and improve kidney perfusion at the same time, and perioperative application may reduce the incidence of postoperative acute kidney injury
Interventions
DRUG
The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
DRUG
The medication is dispensed by the nursing staff before surgery and given to the anesthesiologist before the procedure begins
Timeline
First posted
Oct 31, 2023
Study start
Aug 18, 2023
Primary completion
Jun 30, 2024
Study completion
Jun 30, 2024
Results posted
Not reported
Registry updated
Oct 31, 2023
Outcomes
Incidence of acute kidney injury after liver transplantation
Time frame · in 7 days
acute kidney injury diagnostic criteria (2012 edition)
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * 1\) Patients who plan to undergo liver transplantation in our hospital 2) Patients or family members sign informed consent Exclusion Criteria: * Patients \<18 years old;② Patients undergoing autologous liver transplantation or combined transplantation;③ Patients with lower extremity artery stenosis;(4) Patients with severe heart disease、lung disease、kidney disease;⑤ Patients with severe lung disease;⑥ Patients who used renal replacement therapy before surgery;⑦ the depth of one kidney from the body surface is greater than 4cm;⑧ Patients treated with terlipressin within 2 weeks before surgery⑨ Patients allergic to terlipressin.
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
Beijing Tsinghua Chang Gung Hospital
Beijing, Beijing Municipality, China
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
First Affiliated Hospital, Sun Yat-Sen University · Liver Neoplasms · Postoperative Complications
Not applicable
Completed
161
2026-07
Dayanand Medical College and Hospital · Alcoholic Hepatitis
Phase 3
Active, not recruiting
174
2026-07
Beijing Friendship Hospital · Kidney Transplant · Delayed Graft Function
Not applicable
Active, not recruiting
150
2026-07
University Hospital, Rouen · Bronchial Endoscopy
Phase 3
Completed
130
2026-06
Istanbul Medipol University Hospital · Liver Transplantation · Portal Hypertension
Not applicable
Recruiting
50
2026-04
Assistance Publique - Hôpitaux de Paris · Hemoptysis
Phase 3
Completed
315
2026-04
Noorik Biopharmaceuticals AG · Hepatorenal Syndrome · Liver Cirrhosis
Phase 2
Active, not recruiting
54
2026-04
Institute of Liver and Biliary Sciences, India · Acute-on-Chronic Liver Failure (ACLF)
Not applicable
Not yet recruiting
56
2026-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.